Evidence map›Paper›PMID 41302249›Full record

ReviewHealthcare (Basel, Switzerland)2025

Placebo in Functional Neurological Disorders: Promise and Controversy.

Natalia Szejko, Ali Abusrair, Tomasz Pasierski, Simon Schmitt, Catharina Cramer, Tomasz Pietrzykowski, Anna Dunalska, Kamila Saramak, Katarzyna Śmiłowska, Tereza Serranova and 1 more

Abstract readReview
In one paragraph

Review in Healthcare (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Natalia SzejkoClinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, 30-625 Hannover, Germany.ORCID 0000-0001-6160-9221
Ali AbusrairNeurology Division, Department of Internal Medicine, Qatif Health Network, Qatif 31911, Saudi Arabia.ORCID 0000-0001-9411-1673
Tomasz PasierskiDepartment of Bioethics, Medical University of Warsaw, 02091 Warsaw, Poland.
Simon SchmittClinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, 30-625 Hannover, Germany.ORCID 0000-0003-4004-0587
Catharina CramerClinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, 30-625 Hannover, Germany.ORCID 0009-0009-2171-5682
Tomasz PietrzykowskiDepartment of Law and Administration, University of Silesia in Katowice, 40007 Katowice, Poland.ORCID 0000-0003-0428-7021
Anna DunalskaDepartment of Psychiatry, Faculty of Health Sciences, Medical University of Warsaw, 02091 Warsaw, Poland.ORCID 0000-0002-9489-402X
Kamila SaramakDepartment of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0009-0006-6972-9504
Katarzyna ŚmiłowskaDepartment of Neurology, Regional Specialist Hospital of St. Barbara in Sosnowiec, 41214 Sosnowiec, Poland.ORCID 0000-0001-9167-1624
Tereza SerranovaDepartment of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, 12821 Prague, Czech Republic.ORCID 0000-0001-6525-3971
Kirsten R Müller-VahlClinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, 30-625 Hannover, Germany.ORCID 0000-0002-7181-7419

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Placebo, nocebo, and lessebo effects are very frequent in patients with both neurological and psychiatric disorders. Interestingly, the neural mechanisms underlying placebo effects have been found to be the same as or similar to mechanisms targeted by active pharmaceutical interventions for many of these disorders. In the case of functional neurological disorders (FNDs), there are shared neural substrates between the central nervous system "placebo network" and the dysfunctional networks implicated in the pathophysiology. These networks are primarily involved in emotion regulation, stress responses, and the sense of self-agency. Therefore, placebo effects have also been discussed as therapeutic interventions in FNDs. Such an approach, however, has a variety of ethical implications evolving around informed consent, autonomy, nonmaleficence, beneficence, and justice. In this paper, we discuss the use of placebo, nocebo, and lessebo in FNDs as well as related ethical issues. Overall, the use of placebo in FNDs is currently still considered controversial both for diagnostic as well as therapeutic purposes. Although it is a safe and almost unique intervention, its use violates the core principles of medical ethics and doctor-patient interactions involving autonomy or openness in the therapeutic relationship.

Indexed as

ethicsfunctional neurological disorderslessebo effectnocebo effectplacebo effect

Identifiers

PMID41302249
PMCPMC12652343

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.